UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE
ACT OF 1934
(Amendment No. 1)
Science 37 Holdings, Inc.
(Name of Subject Company)
Science 37 Holdings, Inc.
(Name of Persons Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
808644207
(CUSIP Number of Class of Securities)
Christine Pellizzari
Chief Legal and Human Resources Officer
Science 37 Holdings, Inc.
800 Park Offices Drive, Suite 3606
Research Triangle Park, North Carolina 27709
(984) 377-3737
(Name, address, and telephone numbers of person
authorized to receive notices and communications on behalf of the persons filing statement)
With copies to:
Jurgita Ashley
David Neuhardt
Thompson Hine LLP
3900 Key Center
127 Public Square
Cleveland, Ohio 44114
(216) 566-5500
| ¨ | Check the box if the filing relates
solely to preliminary communications made before the commencement of a tender offer. |
This Amendment No. 1 (this “Amendment No.
1”) amends and supplements the Solicitation/ Recommendation Statement on Schedule 14D-9 (as further amended or supplemented from
time to time, the “Schedule 14D-9”) previously filed by Science 37 Holdings, Inc., a Delaware corporation (the “Company”
or “Science 37”), with the Securities and Exchange Commission on February 12, 2024, relating to the tender offer on Schedule
TO filed with the Securities and Exchange Commission on February 12, 2024, by eMed, LLC, a Delaware limited liability company (“eMed”),
and Marlin Merger Sub Corporation, a Delaware corporation and wholly owned subsidiary of eMed (“Purchaser”), pursuant to the
terms and subject to the conditions of the Agreement and Plan of Merger, dated January 28, 2024 (as it may be amended or supplemented,
the “Merger Agreement”), by and among Science 37, eMed and Purchaser to acquire all of the issued and outstanding shares of
common stock of Science 37, par value $0.0001 per share (the “Shares”), in exchange for $5.75 per Share, net to the seller
in cash, without interest and less any required withholding taxes (the “Offer Price”), upon the terms and subject to the conditions
set forth in the Offer to Purchase, dated February 12, 2024, and the related Letter of Transmittal, as each may be amended or supplemented
from time to time. Any capitalized term used and not otherwise defined herein shall have the meaning ascribed to such term in the Schedule
14D-9.
Following the announcement of the Merger and as
of the filing of this amendment, various demands were received by Science 37, and three lawsuits were filed by purported stockholders
of Science 37 (captioned Ballard v. Science 37 Holdings, Inc., et al., No. 1:24-cv-00200-UNA (D. Del., filed Feb. 14, 2024); McDaniel
v. Science 37 Holdings, Inc., et al, No. 1:24-cv-01090 (S.D.N.Y., filed Feb. 14, 2024); and Lane v. Science 37 Holdings, Inc.,
et al, No. 1:24-cv-01194 (S.D.N.Y., filed Feb. 14, 2024), challenging the disclosures in the Schedule 14D-9 and the Merger. The complaints
and demands assert claims against Science 37 and the Science 37 Board.
Science 37 believes that the allegations in the
complaints and demands lack merit, that no supplemental disclosure is required under applicable laws and that the Schedule 14D-9 disclosed
all material information required to be disclosed therein. However, in order to moot certain of the disclosure claims and to avoid the
risk that lawsuits may delay or otherwise adversely affect the Offer and/or the Merger, and to minimize the expense of defending such
actions, Science 37 determined voluntarily to supplement certain disclosures in the Schedule 14D-9 related to the claims in the complaints
and demands with the supplemental disclosures set forth below (the “Supplemental Disclosures”), all of which should be read
in conjunction with the Schedule 14D-9 in its entirety. Nothing in the Supplemental Disclosures shall be deemed an admission of the legal
merit, necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, Science 37 specifically
denies all allegations in the demands and complaints described above that any additional disclosure was or is required or material.
Except as otherwise set forth below, the information
set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment No.
1. All paragraph headings and page references used herein refer to the headings and pages in the Schedule 14D-9 before any additions or
deletions resulting from the Supplemental Disclosures or any other amendments. To the extent that information in this Amendment No. 1
differs from or updates information contained in the Schedule 14D-9, this Amendment No. 1 shall supersede or supplement the information
in the Statement.
Item 3. Past Contacts, Transactions, Negotiations and Agreements
Item 3 “Past Contacts, Transactions,
Negotiations and Agreements” of the Schedule 14D-9 is hereby amended and supplemented as follows:
1. By deleting the second paragraph under the section
titled “Arrangements Between Science 37 and its Executive Officers, Directors and Affiliates—Employment Agreements—David
Coman Offer Letter” on page 9 and replacing it with the following paragraph:
“Mr. Coman’s offer letter provides
for his participation in Science 37’s Amended Severance Policy (as defined below). Mr. Coman will become entitled to severance benefits
under the Amended Severance Policy if his employment is terminated by Science 37 without “cause” (as
defined in the Amended Severance Policy) or if Mr. Coman resigns for “good reason” (as defined in the Amended Severance Policy).
Pursuant to the Amended Severance Policy, if Mr. Coman becomes entitled to severance under both his offer letter and the Amended Severance
Policy, he will receive the greater of the severance under his offer letter or the severance under the Amended Severance Policy. For a
description of the Amended Severance Policy, see the section below entitled “Severance and Change in Control Benefit Agreements”.”
2. By deleting the second paragraph under the section
titled “Arrangements Between Science 37 and its Executive Officers, Directors and Affiliates—Employment Agreements—Michael
Shipton Employment Agreement” on page 10 and replacing it with the following paragraph
“Mr. Shipton’s employment agreement
provides for his participation in Science 37’s Amended Severance Policy. Mr. Shipton will become entitled to severance benefits
under the Amended Severance Policy if his employment is terminated by Science 37 without “cause” (as
defined in the Amended Severance Policy) or if Mr. Shipton resigns for “good reason” (as defined in the Amended Severance
Policy). Pursuant to the Amended Severance Policy, if Mr. Shipton becomes entitled to severance under both his employment agreement and
the Amended Severance Policy, he will receive the greater of the severance under his employment agreement or the severance under the Amended
Severance Policy. For a description of the Amended Severance Policy, see the section below entitled “Severance and Change in Control
Benefit Agreements”.”
3. By adding the bold and underlined text to
the below paragraph under the section titled “Arrangements Between Science 37 and its Executive Officers, Directors and Affiliates—Future
Arrangements” on page 12 as follows:
“It is possible that Science 37’s executive
officers or directors will enter into new compensation arrangements with eMed or its affiliates. Such arrangements may include agreements
regarding future terms of employment, the right to receive equity or equity-based awards of eMed or retention awards. As of the date of
this Schedule 14D-9, no employment or compensation arrangements between such persons and eMed and/or its affiliates following
the consummation of the Merger have been negotiated or established. Any such arrangements with Science 37’s
executive officers are currently expected to be entered into after the completion of the Offer and will not become effective until after
the Merger is consummated, if at all.”
Item 4. The Solicitation or Recommendation
Item 4 “The Solicitation or Recommendation”
of the Schedule 14D-9 is hereby amended and supplemented as follows:
1. By adding the bold and underlined text to the below
table regarding the January 2024 Projections under the section titled “Certain Unaudited Prospective Information—Important
Information Concerning the Science 37 Management Forecasts and Liquidation Analysis—Forecasts” on page 36 as follows:
| ($ in millions) |
| 2023E | |
| 2024E | |
| 2025E | |
| 2026E | |
| 2027E | |
| 2028E | |
| Revenue |
$ | 59.3 | |
$ | 51.5 | |
$ | 63.7 | |
$ | 77.8 | |
$ | 95.6 | |
$ | 117.6 | |
| YoY % |
| (15.4% | ) |
| (13.1% | ) |
| 23.6% | |
| 22.1% | |
| 22.8% | |
| 23.0% | |
| Adjusted Gross Profit(1) |
$ | 20.4 | |
$ | 21.4 | |
$ | 28.5 | |
$ | 34.9 | |
$ | 43.0 | |
$ | 53.2 | |
| % Margin |
| 34.3% | |
| 41.5% | |
| 44.7% | |
| 44.9% | |
| 45.0% | |
| 45.2% | |
| Adjusted EBIDTA(2) |
$ | (30.4 | ) |
$ | (6.0 | ) |
$ | 0.5 | |
$ | 3.3 | |
$ | 7.0 | |
$ | 10.7 | |
| % Margin |
| N/A | |
| N/A | |
| 0.9% | |
| 4.2% | |
| 7.3% | |
| 9.1% | |
| Capital Expenditures |
$ | 19.7 | |
$ | 4.6 | |
$ | 6.1 | |
$ | 6.1 | |
$ | 6.1 | |
$ | 6.9 | |
| % of Revenue |
| 33.3% | |
| 9.0% | |
| 9.6% | |
| 7.9% | |
| 6.4% | |
| 5.9% | |
| Change in Net Working Capital |
$ | (4.1 | ) |
$ | 0.6 | |
$ | 4.0 | |
$ | 5.6 | |
$ | 0.7 | |
$ | 1.2 | |
| (1) | “Adjusted Gross Profit” is a non-GAAP measure defined as gross profit excluding stock-based compensation expense. |
| (2) | “Adjusted EBITDA” is a non-GAAP measure defined as earnings before interest, taxes, depreciation, and amortization, further
adjusted to exclude expenses and transactions that Science 37 believes are not representative of its core operations, namely: restructuring
and other costs; transaction and integration-related expenses; stock-based compensation expense; impairment losses; other income (expense),
net; and gain or loss on extinguishment of debt. See below a reconciliation of Adjusted EBITDA to net loss. |
| ($ in millions) |
| 2023E | |
| 2024E | |
| 2025E | |
| 2026E | |
| 2027E | |
| 2028E | |
| Net Loss |
$ | (68.8 | ) |
$ | (20.2 | ) |
$ | (11.5 | ) |
$ | (8.8 | ) |
$ | (10.6 | ) |
$ | (12.0 | ) |
| Other (Income) Expense |
$ | — | |
$ | — | |
$ | — | |
$ | — | |
$ | — | |
$ | 2.9 | |
| Change in Fair Value of Earn-Out Liability |
$ | (2.6 | ) |
$ | — | |
$ | — | |
$ | — | |
$ | — | |
$ | — | |
| Impairment of Long-Lived Assets |
$ | 21.1 | |
$ | — | |
$ | — | |
$ | — | |
$ | — | |
$ | — | |
| Depreciation and Amortization |
$ | 0.6 | |
$ | — | |
$ | 3.3 | |
$ | 3.3 | |
$ | 3.3 | |
$ | 3.7 | |
| Restructuring Costs |
$ | 3.6 | |
$ | 1.2 | |
$ | — | |
$ | — | |
$ | — | |
$ | — | |
| Stock-Based Compensation Expense |
$ | 15.6 | |
$ | 13.0 | |
$ | 8.7 | |
$ | 8.8 | |
$ | 14.3 | |
$ | 16.2 | |
| Adjusted EBIDTA |
$ | (30.4 | ) |
$ | (6.0 | ) |
$ | 0.5 | |
$ | 3.3 | |
$ | 7.0 | |
$ | 10.7 | |
2. By adding the bold and underlined text to the below
paragraphs under the section titled “Opinion of William Blair & Company, L.L.C.—Discounted Cash Flow Analysis” on
pages 41 and 42 as follows:
“William Blair utilized the January 2024
Projections to perform a discounted cash flow analysis of Science 37’s projected future free cash flows for the fiscal years ending
December 31, 2024 through December 31, 2028. Using the discounted cash flow methodology, William Blair calculated the present values of
the projected after-tax unlevered free cash flows for Science 37. Unlevered free cash flows were calculated as net operating profit
after tax net of stock-based compensation expense, plus depreciation and amortization, minus capital expenditures, and adjusted for changes
in net working capital. In this analysis, William Blair exercised its professional judgment, based on its experience and expertise,
and calculated the assumed terminal value of Science 37 by utilizing terminal revenue multiples ranging from 0.50x-1.50x calendar year
2028 expected revenue. To discount the projected unlevered free cash flows and assumed terminal value to present value, William Blair
exercised its professional judgment, based on its experience and expertise, and used discount rates ranging from 22.0% to
24.0%. The discount rate range was derived based upon a weighted average cost of capital using the capital asset pricing model.
William Blair aggregated the present value of the
after-tax unlevered free cash flows over the applicable January 2024 Projection period, the present value of the potential tax savings
expected to result from the utilization of Science 37’s federal net operating losses ($1 million), and the present value of the
assumed terminal value. William Blair then derived a range of implied equity values per share by adding Science 37’s net cash of
$51.2 million as of December 31, 2023 and dividing such amount by Science 37’s total diluted Shares outstanding as of January
23, 2024 (consisting of 6,028,167 shares of common stock, 545,971 restricted stock units, 413,024 options, and 625,000 earn-out
shares), as adjusted to take into account the impact of dilutive securities based on the treasury stock method at the implied
share price. This analysis resulted in a range of implied equity values of $4.62 to $11.10 per Share, as compared to the Offer Price.”
3. By adding the bold and underlined text to the below
paragraph under the section titled “Opinion of William Blair & Company, L.L.C.—General” on page 43 as follows:
“William Blair has been engaged in the investment
banking business since 1935. William Blair continually undertakes the valuation of investment securities in connection with public offerings,
private placements, business combinations, estate and gift tax valuations and similar transactions. In the ordinary course of its business,
William Blair may from time to time trade the securities of Science 37 or other parties involved in the Transactions for its own account
and for the accounts of its customers, and accordingly may at any time hold a long or short position in such securities. William Blair
is familiar with Science 37, having provided certain investment banking services to Science 37 from time to time, including as a capital
markets advisor to Science 37. In the two years prior to the date of its written opinion, except for William Blair’s current
engagement, William Blair has not been engaged to provide financial advisory or other services to the Company, and William Blair did not
receive any compensation from the Company during such period. In the two years prior to the date of its written opinion, William Blair
has not been engaged to provide investment banking services to eMed. The Science 37 Board hired William Blair based on its deep
understanding of Science 37’s business, and that William Blair had a significant wealth of experience in both the clinical research
industry and in transactions of this type.”
4. By adding the bold and underlined text to the below
paragraph under the section titled “Opinion of William Blair & Company, L.L.C.—Fees” on page 43 as follows:
“Pursuant to a letter agreement dated March
31, 2023, a fairness opinion fee of $1,500,000 became payable to William Blair promptly after delivery of its fairness opinion. A fee
of approximately $3,500,000, less the $1,500,000 fairness opinion fee previously paid to William Blair, will become payable to William
Blair upon the consummation of the Merger. The Merger Agreement contains a representation of the Company that William Blair had
delivered a favorable fairness opinion with respect to the Merger. No portion of the fees payable to William Blair were contingent
on the conclusions reached by William Blair in William Blair’s fairness opinion. In addition, Science 37 agreed to reimburse William
Blair for certain of its out-of-pocket expenses (including fees and expenses of its counsel and any other independent experts retained
by William Blair) reasonably incurred by it in connection with its services and to indemnify William Blair against certain potential liabilities
arising out of its engagement, including certain liabilities under the U.S. federal securities laws.”
Item 5. Persons/Assets Retained, Employed, Compensated or Used
Item 5 “Persons/Assets Retained, Employed,
Compensated or Used” of the Schedule 14D-9 is hereby amended and supplemented as follows:
1. By adding the bold and underlined text to the below
paragraph on page 43 as follows:
“Science 37 has retained William Blair to
act as its financial advisor in connection with the Transactions. Science 37 selected William Blair based on, among other factors, its
qualifications, professional reputation and industry expertise as well as its deep understanding of Science 37’s business. In connection
with William Blair’s services as a financial advisor to Science 37, Science 37 has agreed to pay William Blair an aggregate fee
of approximately $3,500,000, $1,500,000 of which was payable promptly after the rendering of William Blair’s opinion and the remainder
of which is payable contingent upon consummation of the Transactions. The Merger Agreement contains a representation of the Company
that William Blair had delivered a favorable fairness opinion with respect to the Merger. In addition, Science 37 has agreed to
reimburse William Blair for certain of its expenses arising, and to indemnify William Blair against certain liabilities that may arise,
out of William Blair’s engagement. The Company and eMed may not have elected to proceed with the transaction without a fairness
opinion from William Blair. Additional information pertaining to the retention of William Blair by Science 37 in “Item 4.
The Solicitation or Recommendation — Opinion of William Blair & Company, L.L.C.” is hereby incorporated
by reference in this Item 5.”
Item 8. Additional Information
Item 8 “Additional Information” of
the Schedule 14D-9 is hereby amended and supplemented as follows:
1. By deleting the paragraph under the section titled
“Legal Proceedings” on page 40 and replacing it with the following paragraphs:
“As of this filing, three purported stockholders
of Science 37 have filed complaints in federal court regarding the Transactions. The first complaint was filed on February 14, 2024 in
the United States District Court for the District of Delaware and is captioned Ballard v. Science 37 Holdings, Inc., et al., No.
1:24-cv-00200-UNA. The second and third complaints were filed on February 14, 2024 and February 16, 2024, respectively, in the United
States District Court for the Southern District of New York and are captioned McDaniel v. Science 37 Holdings, Inc., et al, No.
1:24-cv-01090 and Lane v. Science 37 Holdings, Inc., et al, No. 1:24-cv-01194. The aforementioned three complaints are collectively
referred to as the “Complaints.” The Complaints name as defendants Science 37 and each member of the Science 37 Board (collectively,
the “Science 37 Defendants”). The Complaints allege violations of Section 14(d) and Section 14(e) of the Exchange Act, as
well as Rule 14d-9 promulgated thereunder, against all Science 37 Defendants and assert violations of Section 20(a) of the Exchange Act
against the members of the Science 37 Board. The Complaints collectively seek, among other relief, (i) injunctive relief preventing the
consummation of the Transactions; (ii) rescission and/or rescissory damages in the event the Transactions are consummated; (iii) an award
of plaintiffs’ expenses and attorneys’ fees; and (iv) disclosure of certain information requested by the plaintiffs.
In addition, as of this filing, Science 37 had
received 11 demand letters from purported stockholders of the Company, which generally seek that certain allegedly omitted information
in the Schedule 14D-9 be disclosed.
Additional complaints or demand letters may be
filed against or received by Science 37, the Science 37 Board, eMed and/or Purchaser in connection with the Transactions, the Schedule
TO and the Schedule 14D-9. If additional similar complaints are filed or demand letters received, absent new or different allegations
that are material, Science 37 and eMed will not necessarily announce such additional filings.”
SIGNATURE
After due inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: March 4, 2024
| SCIENCE 37 HOLDINGS, INC. |
| |
|
| By: |
|
/s/ David Coman |
| Name: |
|
David Coman |
| Title: |
|
Chief Executive Officer and Director |
Grafico Azioni Science 37 (NASDAQ:SNCE)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Science 37 (NASDAQ:SNCE)
Storico
Da Feb 2024 a Feb 2025
